Plain-English translation of NCT07621783 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a protein called leucine-rich α2-glycoprotein (LRG) to see if it could become a useful blood test for measuring how active inflammatory bowel disease is in your body. Right now, doctors rely on endoscopy (a camera procedure looking inside your colon) and tissue samples to assess disease activity. This study wants to understand whether measuring this protein in your blood could provide another helpful way to track your disease.
Currently, doctors need to perform uncomfortable procedures to know how well your IBD is being controlled. If this blood marker proves reliable, it could eventually help doctors monitor your disease more easily and make treatment decisions faster.
You likely qualify if…
You likely don't qualify if…
You would have a blood sample drawn during your already-scheduled colonoscopy or sigmoidoscopy appointment. The researchers will compare your blood test results with what doctors find during your endoscopy and with tissue samples they may take. This is primarily an observational study, meaning you're not receiving a new medication — researchers are simply collecting information to understand whether this blood marker correlates with what they see during your procedure.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Belgium
Enrollment target
~100 participants
Started
May 2026
Primary completion
December 2026
Age range
16 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peter Bossuyt
Imelda GI Clinical Research Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.